The genes that encode for CYP3A4 and CYP3A5 are located in the same region (CYP3A cluster) on chromosome 7. Midazolam (MDZ) is a substrate for both CYP3A4 and CYP3A5. We hypothesize that MDZ disposition in vivo is associated with genotypes of the CYP3A cluster. A meta-analysis of the pharmacokinetic (PK) parameters from seven clinical trials was carried out, in which MDZ was administered both intravenously and orally. DNA samples were available from 116 patients. There were significant ethnic differences in the allelic frequencies of these four common single-nucleotide polymorphisms (SNPs) in the CYP3A cluster. Significant linkage disequilibrium was found between CYP3A5*3 and CYP3A4*1A in Caucasians, and between CYP3A5*1 and CYP3A4*1B in African Americans. There were no differences in MDZ disposition in vivo between different genotypes, haplotypes and diplotypes in the CYP3A cluster (P40.05). No significant differences in MDZ PK parameters were observed between Caucasians and African Americans. Women had higher weight-corrected systemic and oral clearance than men, but dose-adjusted AUC and bioavailability differences were not observed between sexes. The clinical importance of elevated CYP3A activity in women remains to be determined. The r GC 's of MDZ PK parameters were between 0.3 and 13.6%. In conclusion, the meta-analysis of seven studies suggests that environmental factors explain the majority of CYP3A activity variation. Further studies are necessary to define the functional significance of SNPs in the CYP3A cluster and the effects of CYP3A genotypes on MDZ disposition in vivo.
Introduction
The human CYP3A enzyme subfamily is involved in the oxidative metabolism of a wide range of substrates, including more than 50% of all currently marketed drugs, endogenous steroids and xenobiotic chemicals.
1,2 CYP3A-mediated activity shows approximately 10-fold difference between individuals, which presents a challenge in predicting drug effect and safety. 3 Although concomitant drugs and environment factors partly account for the variability, genetic polymorphisms and variation in expression may play a critical role in betweensubject variability of CYP3A activity. 4, 5 The CYP3A gene cluster, which is located on chromosome 7q22 and spans B220 kb, consists of four genes, including CYP3A4, CYP3A5, CYP3A7 and CYP3A43. 6 CYP3A4 and CYP3A5 are the major metabolism enzymes in adults, and are expressed primarily in the liver and small intestine. CYP3A7 is expressed in fetal liver and plays an important role in the metabolism of endogenous substrates. CYP3A43 is expressed at very low levels in adult human livers. Its contribution to the elimination of CYP3A substrates is regarded to be negligible. 7, 8 Although a number of single-nucleotide polymorphisms (SNPs) at the CYP3A4 locus have been identified, few of them occur frequently enough to contribute to variations in CYP3A activity. As no evidence has shown functionally important allelic mutations in the CYP3A4 coding region, the between-subject variability in CYP3A4 activity may be the result of transcriptional regulation. 1, [9] [10] [11] For instance, the CYP3A4*1B (À392A4G) is a common SNP located in the 5 0 promoter region. The role of this polymorphism on enzyme activity in vivo remains controversial. 9 Functional SNPs are more commonly observed in the CYP3A5 gene. The CYP3A5*3 (6989A4G) SNP in intron 3 introduces a cryptic splice site that results in a frame shift and truncated protein. 12 The CYP3A5*6 (14690G4A) SNP in exon 7 leads to a splicing defect, and the CYP3A5*7 (insertion at 27131_32) SNP in exon 11 results in a premature stop codon. 13, 14 It has been suggested that CYP3A5*6 and CYP3A5*7 be considered together in conjunction with CYP3A5*3 in order to predict significantly diminished CYP3A5 expression. 4 Earlier studies have shown that in Caucasians CYP3A4*1B is in strong linkage disequilibrium with the functional CYP3A5*1. About 80% of Caucasians are homozygous for the CYP3A5*3 and CYP3A4*1A alleles. 15, 16 Midazolam (MDZ), which can be administrated both intravenously and orally, is selectively metabolized by CYP3A4 and CYP3A5 to its primary metabolite, 1 0 -hydroxymidazolam, and is not a substrate of P-glycoprotein. 17, 18 MDZ shows most of the desired characteristics to be used as a probe to measure CYP3A activity, although MDZ clearance may be influenced by hepatic blood flow. [19] [20] [21] [22] [23] [24] Systemic and apparent oral clearances of MDZ are pharmacokinetic (PK) parameters recognized as biomarkers for hepatic and intestinal CYP3A activity. 23, 25 Intravenous (i.v.) administration of MDZ reflects only hepatic CYP3A activity, whereas orally administered MDZ is a measure of intestinal and hepatic CYP3A activities. [25] [26] [27] Simultaneous i.v. and oral (p.o.) MDZ administration has been used to examine the individual contributions of intestinal and hepatic CYP3A to metabolism. [25] [26] [27] Although remarkable ethnic differences exist within the CYP3A cluster structure, the genetic component of variability (that is, between-subject variability) remains uncertain. [28] [29] [30] Some studies also suggest that there are sex differences in CYP3A activity, but the results are inconsistent. [31] [32] [33] The objectives of our study are to investigate whether i.v. and p.o. MDZ disposition in vivo is associated with genotypes of the CYP3A cluster, ethnicity, sex or age in healthy volunteers and to understand the genetic component of its variability.
Materials and methods

Study design
We reviewed seven clinical trials conducted from 1998 to 2003 by our research team (Table 1) . In each study, singledose MDZ was administrated both i.v. and p.o. In five studies, subjects were simultaneously administered a single i.v. dose (0.05 mg kg À1 over 30 min) of MDZ and an oral dose of 15 N-MDZ (3 mg) after an overnight fast. In two additional studies, oral MDZ (4 mg) was administered 24 h after the i.v. dose. All drugs and food known to affect CYP3A activity were prohibited before and during the studies. For each subject, blood samples for MDZ concentrations were obtained over a period of 12-24 h. The sample sizes varied among studies ( Table 1 ). The MDZ serum concentrations were determined using a previously published method. 34, 35 PK parameter estimates were calculated using non-compartmental methods (WinNonLin 4.0; Pharsight, Mountain View, CA, USA). Dose-adjusted i.v. and p.o. area under the concentration-time curve (AUC), weight-corrected i.v. and p.o. clearance (CL), and bioavailability (F) were used as MDZ PK parameters, as dosages were different in these seven trials and body size seems to be an important determinant of between-subject variability. 36 Blood was also collected for DNA analysis.
Study population
These seven clinical trials were approved by the Institutional Review Board of Indiana University-Purdue University Indianapolis and informed consent was obtained from each of the 176 volunteers who participated. Subjects were healthy as determined by medical history, physical examination, 12-lead electrocardiogram and laboratory screening. DNA samples were collected from 116 subjects among the cohort (Table 1) .
Genotyping methods
Genomic DNA was extracted from whole blood and isolated using a QIAamp DNA blood Midi Kit (Qiagen, Valencia, CA, USA). DNA concentration was detected by SmartSpec Plus spectrophotometry (BIO-RAD, Hercules, CA, USA). All DNA samples were genotyped for CYP3A5*3 (6986A4G), CYP3A5*6 (14690G4A), CYP3A5*7 (insertion at 27131_32) and CYP3A4*1B (-392A4G). The genotyping of CYP3A5*3, *6 and *7 was determined using real-time PCR as described earlier.
14 The CYP3A4*1B allele was detected with a TaqMan assay from the CGAP Web site (SNP500Cancer, dsSNP ID: rs2740574) and confirmed by sequencing.
Statistical considerations
The distributions of demographic data were inspected visually. Genotype frequencies were tested for departure from Hardy-Weinberg equilibrium using w 2 -test with 1 degree of freedom. Frequencies of the four CYP3A SNPs were highly variable among ethnic groups and therefore population-specific pairwise linkage disequilibrium and haplotype frequencies were estimated using Haploview (Ver 3.1, from http://www.broad.mit.edu/ mpg/haploview/). We stratified the genotype data based on ethnic background and determined CYP3A5 and CYP3A4*1B haplotype using PHASE II software (Version 2.1, from http://www.stat. washington.edu/stephens/phase). The overall differences in the PK parameters among patients with different CYP3A5 and CYP3A4*1B genotypes were tested by F-tests in one-way ANOVA with repeated measures, and (dominance, recessive, gene-dose) effects of these genetic polymorphisms on PK parameters were compared by Student's t-tests. The Student's t-test was also used to compare the PK parameters of MDZ with regard to ethnicity, sex and age. PK parameters were log-transformed, and their population between-subject variance, s 2 B , and within-subject variance, s 2 W , were estimated with the linear mixed model (PROC MIXED, SAS 9.1 Cary, NC, USA). The genetic component was estimated as
37,38 Please note that this genetic component estimate is different from the formula proposed by Kalow et al. 37 As our SAS PROC MIXED s 2 B and s 2 W estimates are unbiased for between-subject and within-subject variances, respectively, our genetic component estimate does not have the bias correction.
Results
Study characteristics
Pharmacokinetic parameters of MDZ were collected from seven clinical trials, in which single-dose MDZ was administrated both i.v. and p.o. Results of some these seven studies have been published earlier (Table 1) .
Subject characteristics
A total of 116 subjects in these seven trials had both MDZ disposition data and CYP3A cluster genotype data and were therefore used in this analysis. Among these 116 subjects, 64 subjects participated in only one trial and 22 subjects participated in 2-3 different clinical trials. The characteristics of all the 116 subjects and in groups based on the CYP3A5 haplotype are summarized in Table 2 . There were significant differences among the three CYP3A5 haplotype groups with respect to ethnicity, sex and age (Po0.05).
Genotype determination
Among the total number of 116 subjects, the allele frequencies of CYP3A5*1, *3, *6 and *7 were 0.9, 1.7, 19.0 and 78.4%, respectively. The most common genotype was CYP3A5*3*3. There was only one CYP3A5*6*6 and no CYP3A5*7*7 homozygotes in this cohort. The allele frequency of CYP3A4*1B was 20.7% in this population. The distribution of each allele satisfied the Hardy-Weinberg equilibrium (Table 3) . We combined *3, *6 and *7 variant alleles into one CYP3A5 non-expresser allele group referred to as the *0 allele, because none of them produce any functional CYP3A5 protein.
14 Ten subjects (8.6%) were classified as *1*1 homozygous expressers who were *1*1 for all three SNPs. Twenty-four (20.7%) subjects were classified as *1*0 heterozygous expressers who carried only one of *3, *6 or *7. Eighty-two (70.7%) subjects were classified as nonexpressers who were either homozygous for *3*3, *6*6 or *7*7 or carried one *3 and *6, one *3 and *7 or one *6 and *7.
Diplotype is the most likely pair of genotypes in each individual. We combined CYP3A5 genotype and CYP3A4*1B genotype to determine the diplotype of the CYP3A cluster and coded them into nine groups. The diplotype distribution of the CYP3A cluster was significantly different in Caucasians and in African Americans (Table 4) . In Caucasians, neither CYP3A5*6 nor CYP3A5*7 was found. In all, 81.8% of subjects homozygous for CYP3A5*3 were also homozygous for CYP3A4*1A. Significant linkage disequilibrium was found between CYP3A5*3 and CYP3A4*1A in Caucasians (D 0 ¼ 0.716). The diplotypes in African Americans were more decentralized than in Caucasians, because the frequency of the CYP3A4*1B allele was much higher in African Americans (78.8%) than in Caucasians (4.0%). A linkage disequilibrium was found between CYP3A5*1 and CYP3A4*1B in African Americans (D 0 ¼ 0.581).
The association between CYP3A genotype and MDZ PK As CYP3A5 shows overlap in its cDNA sequence identity, and substrate specificities with CYP3A4, genotyping for CYP3A genetic/non-genetic in vivo variations with MDZ J Miao et al CYP3A5/3A4 haplotype or diplotype is necessary to understand the variations in the metabolism and clinical toxicity of drugs. 39, 40 With regard to CYP3A5*3 and CYP3A4*1B polymorphisms, there were no significant differences in PK parameters of MDZ, including dose-adjusted AUC and weight-corrected CL after i.v. or p.o. administration, or bioavailability (Table 5 ). There were no significant differences in MDZ disposition among the nine CYP3A diplotype groups (P40.05, data not shown). The groups of diplotype code 1 (homozygous for CYP3A5*1/*1 and CYP3A4*1B/*1B) and the group of code 9 (homozygous for CYP3A5*0/*0 and CYP3A4*1A/*1A) may be considered to show the maximum discrepancy between diplotypes, because both CYP3A5*1 and CYP3A4*1B may increase CYP3A activity. However, there were no significant differences in i.v. or p.o. MDZ PK parameters between these two diplotype groups. 2 of 116 subjects were Asians whose diplotypes were both code 3. We combined *3, *6 and *7 variant alleles into one CYP3A5 non-expresser allele group referred to as the *0 allele.
CYP3A genetic/non-genetic in vivo variations with MDZ J Miao et al
The association between population traits and MDZ PK Population estimates of the PK parameters of MDZ are summarized in Table 6 . Women showed a 19.4% higher i.v. weight-corrected CL (P ¼ 0.016) and 38.2% higher p.o. weight-corrected CL (P ¼ 0.026) than men ( Figure 1 ). There were no statistically significant differences for i.v. and p.o. dose-adjusted AUC or bioavailability between women and men (P40.05). No statistically significant differences for i.v. and p.o. MDZ disposition were observed between Caucasians and African Americans or between young and elderly patients (29.5 ± 1.1 vs 70.8 ± 0.6 years).
In the 62 young subjects who were 19-55 years old, there were no significant differences in i.v. or p.o. MDZ PK parameters relative to the CYP3A cluster genotype (data not shown).
Population between-/within-subject variances and genetic component of variability of MDZ PK parameters Table 7 shows the between-and within-subject variance for the MDZ PK parameters. 
Discussion
Although some earlier studies have shown that CYP3A5*1 alleles are associated with greater intestinal CYP3A activity, and that affecting CYP3A4 transcription is relevant for between-subject differences in CYP3A4 enzyme expression, the primary in vivo mechanism and contribution of nongenetic factors to CYP3A variability is not clear. 4, 11, 30, 41, 42 Our study found that the allelic frequencies of these four SNPs in the CYP3A cluster are highly different between ethnic groups. The most common variant CYP3A5*3 had a frequency of 92.0% in Caucasians and 36.5% in African Americans, consistent with literature reports of 85-95% in Caucasians, 60-73% in Asians and 27-50% in African Americans. 6, 13, 14 The allelic frequencies of CYP3A4*1B in African Americans and in Caucasians in our study were 78.8 and 4.0%, respectively. This is also consistent with the CYP3A4*1B allele frequency being much higher in African Americans (54.6%) than in Hispanic Americans (9.3%) and Caucasians (3.6%) in other studies. 5, 11 The haplotypes and diplotypes in African Americans were significantly different from Caucasians. Linkage disequilibrium was observed between CYP3A5*3 and CYP3A4*1A alleles in Caucasians, but between the CYP3A5*1 and CYP3A4*1B alleles in African Americans.
Although the allelic frequencies of the CYP3A genes were highly different among ethnic groups, no significant difference in MDZ disposition in vivo between Caucasians and African Americans was observed (P40.05). Genetic polymorphisms in the CYP3A cluster were not associated with MDZ disposition. No significant association was observed between genotypes, haplotypes or diplotypes in the CYP3A locus and MDZ PK parameters (P40.05). These results were consistent with earlier studies of smaller size. 29, 36, 43, 44 Using MDZ as an in vivo probe in 57 healthy European-and African-American subjects, Floyd et al. reported that the variability of hepatic and intestinal CYP3A activity was modest. 29 In addition, the common polymorphisms of CYP3A4*1B, CYP3A5*3, CYP3A5*6 and CYP3A5*7 did not seem to have important functional significance. Similarly, no significant genotype-phenotype or haplotype-phenotype associations for any of the CY-P3A4*1B, CYP3A5*3 and CYP3A5*6 SNPs or haplotypes were found in 27 healthy volunteers receiving oral MDZ. 43 Tateishi et al. 36 found no statistically significant or clinically important inter-ethnic differences in CYP3A activity evident between 20 Caucasians and 22 Japanese, using MDZ as an in vivo probe. Despite affecting the metabolism of MDZ in human liver microsomes, CYP3A5 genotype had no effect on the systemic or apparent oral clearances of MDZ or alfentanil among 99 healthy volunteers. 44 Clearances were not different between African Americans (n ¼ 25) and Caucasians (n ¼ 68) or among CYP3A5 genotype groups within African Americans. 44 These results indicate that the CYP3A genetic variants identified so far have only a limited effect on MDZ metabolism in vivo.
As between-subject variations in CYP3A expression and activity are because of a combination of genetic and nongenetic factors such as hormone, health status and environmental stimuli, 4 these non-genetic factors may play a greater role in CYP3A variability. We examined this using a modified statistical estimate proposed by Kalow et al. 37, 38 to calculate the r GC . The lack of evidence of CYP3A genetic effect is partially reflected by the low genetic component, r GC , of the MDZ PK parameters. Estimates of r GC among the 22 subjects who participated in more than one trial ranged from 0.3 to 13.6%. Ozdemir et al. 38 used a similar repeated drug administration method to evaluate the genetic component of variability in CYP3A activity. They calculated the r GC for hepatic CYP3A4 activity through MDZ plasma clearance as 0.96 (95% Cl ¼ 0.92-0.98). However, multiple MDZ doses for this study were obtained within 3 months, 45 whereas multiple data from our subjects were obtained within a time span of up to 3 years. In addition, the majority of subjects enrolled in multiple studies in our dataset were elderly individuals, compared with the study by Ozdemir et al., in which subjects were much younger. In both studies, all subjects were nonsmokers, did not use concomitant medications and were monitored for their diet to avoid exposure to food effects. Hence, the environmental exposure was minimized, while the genetic component was maximized. In our meta-analysis from multiple studies, we found that the r GC 's of CYP3A activity by MDZ clearance and AUC ranged from 0.3 to 13.6%. In other words, between-subject variances are much smaller than withinsubject variances. This observation hints that environmental factors are more dominant and important than inherited genetic factors in CYP3A activity, if more extensive environmental effects are considered. However, given that CYP3A genetic effect is only a part of r GC , it is difficult to test the CYP3A genetic effect with only a small or moderate sample size.
Studies regarding sex differences in CYP3A activity have produced conflicting results. Many CYP3A substrates show higher clearance in women than in men. Wolbold et al. 33 found a two-fold higher CYP3A4 messenger RNA (mRNA) transcripts in human liver in female compared with male 46 reported that CYP3A activity was higher in women than in men, and CYP3A activity differed across the phases of the menstrual cycle in Chinese subjects. Chen et al. reviewed data from 13 earlier studies and found that women showed 11% higher mean weight-corrected total MDZ clearance and 28% higher oral clearance compared with men. Although significantly greater hepatic and intestinal CYP3A activities were shown in women, only a minor sex difference in AUC was observed. 31, 32 On the other hand, studies by He et al. 43 and Greenblatt et al. 47 showed no sex differences in CYP3A activity. In our present study, women had higher weight-corrected systemic and oral clearance than men, indicating that CYP3A activity may be greater in women. However, there were no significant differences of systemic and oral clearance between women and men, because women had much lower body weight than men. In addition, dose-adjusted AUC and bioavailability differences were not observed between sexes. Therefore the clinical importance of elevated CYP3A activity in women remains to be determined. Greenblatt et al. evaluated the age effect on CYP3A activity with triazolam. AUC increased and clearance declined with increased age in men, whereas age had no significant effect on AUC or clearance in women. Although the findings were consistent with reduced clearance in elderly men, individual variability was large and was not explained by identifiable demographic or environmental factors. 32 We did not find any age effect on MDZ PK parameters in our study.
Conclusions
Significant ethnic differences were found in CYP3A allelic frequencies within the CYP3A cluster. The haplotypes and diplotypes in African Americans were significantly different from Caucasians. No significant difference was observed in MDZ disposition in vivo between genotypes, haplotypes and diplotypes in the CYP3A locus (P40.05), nor between Caucasians and African Americans. Women had higher weight-corrected systemic and oral clearance than men, but dose-adjusted AUC and bioavailability differences were not detected between sexes. The clinical importance of elevated CYP3A activity in women remains to be determined. The r GC 's of MDZ PK parameters were between 0.3 and 13.6%, indicating that the environmental factors explain a much larger variation in CYP3A activity than genetics. However, the effects of CYP3A genotype on drug disposition in vivo continue to warrant further investigation.
